Michael Best, MD
Family Medicine · Michigan City, INNPI 1083621510
Payments from drug & device makers
Across 52 payments — averaging $14.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$90
- Sanofi-aventis U.S. LLC$82
- Lilly USA, LLC$73
- Amarin Pharma, Inc.$66
- AstraZeneca$56
- Novo Nordisk$51
- plus $316 from 13 others
What the payments were for
- Food & beverage$72298%
- Education$122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $90 |
| Sanofi-aventis U.S. LLC | 6 | $82 |
| Lilly USA, LLC | 6 | $73 |
| Amarin Pharma, Inc. | 5 | $66 |
| AstraZeneca | 4 | $56 |
| Novo Nordisk | 4 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $37 |
| Merck | 3 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $34 |
| Johnson & Johnson | 2 | $34 |
| AbbVie | 3 | $22 |
| Boston Scientific | 1 | $21 |
| Gilead | 1 | $20 |
| GSK | 1 | $20 |
| Inari Medical, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Pfizer | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$734 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 103 | $123,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $60,043 |
| EliquisApixaban | 80 | $59,187 |
| JardianceEmpagliflozin | 32 | $39,832 |
| XareltoRivaroxaban | 46 | $37,365 |
| OzempicSemaglutide | 30 | $31,725 |
| JanuviaSitagliptin Phosphate | 15 | $25,311 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $21,199 |
| RexultiBrexpiprazole | 12 | $18,518 |
| FarxigaDapagliflozin Propanediol | 18 | $16,894 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $13,514 |
| Spiriva RespimatTiotropium Bromide | 21 | $10,720 |
| Solifenacin Succinate | 91 | $9,392 |
| EntrestoSacubitril/Valsartan | 12 | $8,626 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $8,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $73 | $123,510103 claims |
| GSKTrelegy Ellipta | $20 | $60,04377 claims |
| PfizerEliquis | $13 | $59,18780 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $34 | $50,55253 claims |
| Johnson & JohnsonXarelto | $34 | $37,36546 claims |
| Novo NordiskOzempic | $51 | $31,72530 claims |
| MerckJanuvia | $36 | $25,31115 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $36 | $18,51812 claims |
| AstraZenecaFarxiga | $56 | $16,89418 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $37 | $5,16713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Michigan City
- James CallaghanMichigan City$30K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.